Tuis8QQ • FRA
add
AbCellera Biologics Inc
Vorige sluiting
€1,78
Dagwisseling
€1,78 - €1,78
Jaarwisseling
€1,70 - €3,79
Markkapitalisasie
588,01 m USD
Gemiddelde volume
448,00
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(USD) | Mrt. 2025info | J/J-verandering |
---|---|---|
Inkomste | 4,24 m | -57,45% |
Bedryfskoste | 24,40 m | -4,55% |
Netto inkomste | -45,62 m | -12,34% |
Netto winsgrens | -1,08 k | -164,04% |
Wins per aandeel | -0,15 | -7,14% |
EBITDA | -57,33 m | -14,54% |
Effektiewe belastingkoers | 13,90% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(USD) | Mrt. 2025info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 605,27 m | -13,29% |
Totale bates | 1,34 mjd | -8,13% |
Totale aanspreeklikheid | 321,23 m | -3,59% |
Totale ekwiteit | 1,02 mjd | — |
Uitstaande aandele | 298,48 m | — |
Prys om te bespreek | 0,52 | — |
Opbrengs op bates | -11,58% | — |
Opbrengs op kapitaal | -14,16% | — |
Kontantvloei
Netto kontantverandering
(USD) | Mrt. 2025info | J/J-verandering |
---|---|---|
Netto inkomste | -45,62 m | -12,34% |
Kontant van bedrywe | -11,55 m | 72,30% |
Kontant van beleggings | 7,94 m | -73,47% |
Kontant van finansiering | 5,97 m | 110,88% |
Netto kontantverandering | 2,94 m | 130,17% |
Beskikbare kontantvloei | -63,60 m | -21,59% |
Meer oor
AbCellera Biologics Inc. is a Vancouver, British Columbia-based contract research organization that is contracted by biotechnology and pharmaceutical companies for antibody services, and researches and develops human antibodies as a service for its clients. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. Wikipedia
HUB
Gestig
2012
Hoofkwartier
Webwerf
Werknemers
596